Edition:
United States

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

6.10USD
18 May 2018
Change (% chg)

-- (--)
Prev Close
$6.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
36,652
52-wk High
$8.25
52-wk Low
$3.20

Chart for

About

Arbutus Biopharma Corp is a Canada-based company engaged in biopharmaceutical sector. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company is focused on a process of... (more)
No analyst recommendations are available for .

Overall

Beta: 0.72
Market Cap(Mil.): $454.57
Shares Outstanding(Mil.): 55.14
Dividend: --
Yield (%): --

Financials

  ABUS.OQ Industry Sector
P/E (TTM): -- 28.57 32.53
EPS (TTM): -2.20 -- --
ROI: -51.57 13.08 12.63
ROE: -55.72 14.80 14.50

BRIEF-Arbutus Announces Corporate Update

* ARBUTUS ANNOUNCES CORPORATE UPDATE AND YEAR-END 2017 FINANCIAL RESULTS

Mar 14 2018

BRIEF-Arbutus Settles Litigation Terminating Acuitas Rights To LNP Technology

* ARBUTUS SETTLES LITIGATION, TERMINATING ACUITAS’ RIGHTS TO LNP TECHNOLOGY

Feb 22 2018

BRIEF-Arbutus Enters Exclusivity Agreement With Roivant Sciences

* ARBUTUS ENTERS EXCLUSIVITY AGREEMENT WITH ROIVANT SCIENCES Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

Feb 14 2018

BRIEF-Arbutus Announces Departure Of CFO Bruce Cousins

* ARBUTUS ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER; APPOINTS INTERIM CFO

Feb 13 2018

BRIEF-Arbutus Consolidates HBV Business Around Warminster, PA Site

* ARBUTUS BIOPHARMA CORP - SITE CONSOLIDATION AND ORGANIZATIONAL RESTRUCTURING TO BETTER ALIGN ITS HBV BUSINESS IN WARMINSTER, PA

Feb 08 2018

Earnings vs. Estimates